Search Result

Results for "

EMT

" in MCE Product Catalog:

By Targets:	Akt (2) Antibiotic (2) Apoptosis (13) Aurora Kinase (1) Autophagy (1) Bacterial (1) Bcl-2 Family (3) c-Myc (1) CDK (1) COX (2) CRM1 (1) Cytochrome P450 (2) DNA/RNA Synthesis (1) EGFR (1) FAK (2) Ferroptosis (2) FLT3 (1) Fungal (1) Hippo (MST) (1) Histone Demethylase (1) Integrin (1) JNK (1) MAP4K (1) Microtubule/Tubulin (1) MMP (1) Myosin (1) Notch (1) p38 MAPK (1) p97 (1) PDGFR (1) Phosphatase (3) PI3K (1) Proteasome (1) Reactive Oxygen Species (1) SHP2 (1) STAT (1) TAM Receptor (1) TGF-beta/Smad (2) TGF-β Receptor (3) TrxR (1) VEGFR (1) Wnt (2)
By Research Areas:	Cancer (33) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (1)

By Targets:

Akt (2)

Antibiotic (2)

Apoptosis (13)

Aurora Kinase (1)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (3)

c-Myc (1)

CDK (1)

COX (2)

CRM1 (1)

Cytochrome P450 (2)

DNA/RNA Synthesis (1)

EGFR (1)

FAK (2)

Ferroptosis (2)

FLT3 (1)

Fungal (1)

Hippo (MST) (1)

Histone Demethylase (1)

Integrin (1)

JNK (1)

MAP4K (1)

Microtubule/Tubulin (1)

MMP (1)

Myosin (1)

Notch (1)

p38 MAPK (1)

p97 (1)

PDGFR (1)

Phosphatase (3)

PI3K (1)

Proteasome (1)

Reactive Oxygen Species (1)

SHP2 (1)

STAT (1)

TAM Receptor (1)

TGF-beta/Smad (2)

TGF-β Receptor (3)

TrxR (1)

VEGFR (1)

Wnt (2)

By Research Areas:

Cancer (33)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (3)

Metabolic Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas

HY-128859

EMT inhibitor-2	Cytochrome P450	Metabolic Disease
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC₅₀s of 49.72 and 5.54 μM, respectively.

HY-101275

EMT inhibitor-1
Hippo (MST) TGF-beta/Smad Wnt Cancer

EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.

EMT inhibitor-1	Hippo (MST) TGF-beta/Smad Wnt	Cancer
EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.

HY-152084

Anticancer agent 93	Others	Cancer
Anticancer agent 93 is a 4-Hydroxycoumarin derivative. Anticancer agent 93 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors.

HY-152085

Anticancer agent 94	Others	Cancer
Anticancer agent 94 is a 4-Hydroxycoumarin derivative. Anticancer agent 94 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors.

HY-B0449

Methacycline hydrochloride	Bacterial Antibiotic	Infection
Methacycline hydrochloride is a tetracycline antibiotic and can inhibits bacterial protein synthesis. Methacycline hydrochloride is a potent epithelial-mesenchymal transition (EMT) inhibitor. Methacycline hydrochloride blocks EMT in vitro and fibrogenesis in vivo without directly affecting TGF-β1 Smad signaling. Methacycline hydrochloride is an antimicrobial and has the potential for pulmonary fibrosis.

HY-151904

AXL-IN-13	TAM Receptor FLT3 PDGFR	Cancer
AXL-IN-13 is a potent and orally active AXL inhibitor (IC₅₀: 1.6 nM, K_d: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.

HY-151802

CPUL1	TrxR	Cancer
CPUL1 is a TrxR inhibitor, which shows proliferation-inhibitory and anti-metastatic activity against A549 cells. CPUL1 influences EMT (epithelial-mesenchymal transition) via inducing ROS-mediated ERK/JNK signaling by inhibiting TrxR1 enzyme activity. CPUL1 in combination with α-Lipoic Acid (HY-N0492) or Dithiodipropionic acid (HY-W014395) is more effective.

HY-N6896

Isoviolanthin	TGF-beta/Smad	Cancer
Isoviolanthin, a flavonoid glycoside, could markedly inhibit TGF-β1-mediated migration and invasion by deactivating epithelial-mesenchymal transition (EMT) via the TGF-β/Smad and PI3K/Akt/mTOR pathways in HCC cells. Isoviolanthin exhibits no cytotoxic effects on normal liver LO2 cells.

HY-18766

EW-7195	TGF-β Receptor p38 MAPK	Cancer
EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC₅₀ of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung.

HY-151429

Antitumor agent-77	Apoptosis Ferroptosis Bcl-2 Family COX	Cancer
Antitumor agent-77 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-77 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-77 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells.

HY-151428

Antitumor agent-78	Ferroptosis Apoptosis Bcl-2 Family COX	Cancer
Antitumor agent-78 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-78 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-78 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells.

HY-138657

NCGC00378430	Phosphatase	Cancer
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT). NCGC00378430 inhibits SIX1-mediated breast cancer metastasis in a mouse model.

HY-12564

Phthalazinone pyrazole	Aurora Kinase Apoptosis	Cancer
Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC₅₀ of 0.031 μM. Phthalazinone pyrazole can arrests mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells. Phthalazinone pyrazole suppresses the epithelial-mesenchymal transition (EMT) during the differentiation of hepatocyte-like cells (HLCs) from human embryonic stem cells.

HY-103038

ML327
c-Myc Autophagy Cancer

ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

ML327	c-Myc Autophagy	Cancer
ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

HY-151976

STAT3-IN-15	STAT	Inflammation/Immunology
STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT).

HY-N7972

19-Oxocinobufotalin	Others	Cancer
19-Oxocinobufotalin is capable of suppressing EMT (Epithelial-mesenchymal transition) and weakening the migratory and invasive potential of PC3 cells.

HY-122965

Batatasin III	FAK Akt	Cancer
Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities.

HY-N10335

Harringtonolide	FAK	Cancer Inflammation/Immunology
Harringtonolide is a potent RACK1 inhibitor (IC₅₀=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between FAK and RACK1. Harringtonolide has plant growth inhibitory, antiviral, anti-inflammatory, and antiproliferation activities.

HY-147768

PI3K/AKT-IN-2	PI3K Akt Microtubule/Tubulin MMP Apoptosis	Cancer
PI3K/AKT-IN-2 (Compound 12c) is a PI3K and AKT inhibitor. PI3K/AKT-IN-2 blocks the epithelial-mesenchymal transition (EMT) and induces apoptosis. PI3K/AKT-IN-2 inhibits the polymerization of tubulin.

HY-115669

Pentachloropseudilin Antibiotic A 15104 Y; PClP	Myosin TGF-β Receptor	Cancer
Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC₅₀s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β)-stimulated signaling, with an IC₅₀ of 0.1 to 0.2 μM for TGF-β.

HY-146693

CJJ300	TGF-β Receptor	Cancer
CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC₅₀ of 5.3 µM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex.

HY-135967

MTH1-IN-2	DNA/RNA Synthesis	Cancer
MTH1-IN-2 is a MutT homolog 1 (MTH1) inhibitor extracted from patent WO2016135138A1, Compound (6), MTH1-IN-2 can be used for the research of cancer. Anti-tumor activity.

HY-P99589

Sotevtamab 16B5; AB-16B5	Apoptosis	Cancer
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research.

HY-124745

KY-05009	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity.

HY-143323

HER2-IN-9	EGFR	Cancer
HER2-IN-9 is an orally active HER2 inhibitor, with an IC₅₀ value of 0.03 μM. HER2-IN-9 inhibits HER-2 positive breast cancer cells proliferation and migration. HER2-IN-9 can be used in the research of breast cancers.

HY-152079

CYP1B1-IN-3	Cytochrome P450	Cancer
CYP1B1-IN-3 is a potent and selective CYP1B1 inhibitor with IC₅₀ values of 6.6, 347.3, >10000 nM for CYP1B1, CYP1A1, CYP1A2, respectively. CYP1B1-IN-3 inhibits cell migration and invasion. CYP1B1-IN-3 inhibits P-gp, AKT/ERK, FAK/SRC, and EMT pathways.

HY-123931

ZLDI-8	Notch Phosphatase Apoptosis	Cancer
ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC₅₀ of 31.6 μM and a K_i of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC₅₀ of 5.32 μM.

HY-150596

CT1-3	Apoptosis Bcl-2 Family JNK	Cancer
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity.

HY-110078

Eeyarestatin I	p97 Apoptosis	Cancer
Eeyarestatin I, a potent endoplasmic reticulum-associated protein degradation (ERAD) inhibitor, is a potent protein translocation inhibitor. Eeyarestatin I inhibits Sec61 translocon. Eeyarestatin I targets the p97-associated deubiquitinating process (PAD) and inhibits atx3-dependent deubiquitination. Eeyarestatin I interferes at a step prior to proteasomal degradation. Eeyarestatin I induces cell death via the proapoptotic protein NOXA and has anticancer effects.

HY-148713

Anti-CSCs agent-1	Apoptosis	Cancer
Anti-CSCs agent-1 is a potent anti-CSCs agent. Anti-CSCs agent-1 inhibits cell growth and cell migration. Anti-CSCs agent-1 induces Apoptosis. Anti-CSCs agent-1 inhibits the viability of CSCs. Anti-CSCs agent-1 enhances the production of ROS in CSCs. Anti-CSCs agent-1 shows antitumor activity.

HY-149968

LSD1-IN-25	Histone Demethylase Apoptosis	Cancer
LSD1-IN-25 (Compound 9j) is a potent, selective and orally active LSD₁ inhibitor with an IC₅₀ of 46 nM (K_i = 30.3 nM). LSD1-IN-25 induces cancer cell apoptosis.

HY-143491

VS 8	VEGFR Apoptosis Reactive Oxygen Species	Cancer
VS 8 (Compound VS 8) is a potent, orally active VEGFR-2 inhibitor with significant anti-angiogenic effects. VS 8 induces cancer cell apoptosis and migration. VS 8 is active against CSCs (Cancer stem cells).

HY-150609

SHP2/CDK4-IN-1	SHP2 Phosphatase CDK	Cancer
SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC₅₀ values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research.

HY-16909

Leptomycin B CI 940; LMB	CRM1 Fungal Antibiotic	Cancer Infection
Leptomycin B (CI 940; LMB) is a potent inhibitor of the nuclear export of proteins. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue. Leptomycin B is a potent antifungal antibiotic blocking the eukaryotic cell cycle.

HY-110112

BTT-3033	Integrin Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC50: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen Ⅰ and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease.

HY-151424

Vimentin-IN-1	Proteasome	Cancer
Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin (VIM), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and multinucleation in transformed VIM-expressing mesenchymal cancer cells. Vimentin-IN-1 shows better oral bioavailability and pharmacokinetic profiles than FiVe1.

Cat. No.	Product Name	Target	Research Area